Dosing Reliability of Direct Thrombin Inhibitors in Extracorporeal Membrane Oxygenation: A Systematic Review and Meta-Analysis
Meta-analysis published in ASAIO journal (American Society for Artificial Internal Organs : 1992) (2025)
Abstract
Empirical evidence suggests direct thrombin inhibitors (DTIs) produce more favorable hemostatic outcomes than heparin in patients supported by extracorporeal membrane oxygenation (ECMO), yet the exact mechanisms responsible are unknown. We systematically searched databases and registers for studies comparing DTIs to heparin in humans receiving ECMO. A total of 28 studies were identified, most of which (n = 25) used bivalirudin, while the rest (n = 3) used argatroban. In random-effects meta-analysis, DTIs achieved the therapeutic anticoagulation range faster (mean difference = -6.96 hours, 95% confidence interval [CI] = -11.98 to -1.95, p = 0.006) and maintained the therapeutic range for a greater proportion of time (mean difference = 18.6%, 95% CI = 8.78-28.42, p < 0.001) than heparin. Subgroup analysis revealed these effects were similarly significant in adult patients and when bivalirudin was the DTI; however, they were not significant in pediatric patients or when argatroban was the DTI. Sensitivity analysis confirmed robustness of the primary findings in only low-risk of bias studies and in only studies published as full papers. In summary, DTIs-specifically bivalirudin-were associated with faster time to therapeutic anticoagulation and maintained the goal range for a greater percentage of time than heparin during ECMO support.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Summary
A random-effects meta-analysis of 28 ECMO studies (25 using bivalirudin, 3 argatroban) found direct thrombin inhibitors reached therapeutic anticoagulation faster (mean difference −6.96 hours) and maintained the therapeutic range longer (mean difference 18.6%) than heparin.
Why This Matters for Hirudotherapy
This systematic review and meta-analysis identified 28 studies comparing direct thrombin inhibitors (DTIs) with heparin for anticoagulation during extracorporeal membrane oxygenation, finding that DTIs—predominantly bivalirudin (25 studies), with argatroban in 3—achieved therapeutic anticoagulation faster and maintained it for a greater proportion of time than heparin. Subgroup analyses showed significance in adults and with bivalirudin but not in pediatric patients or with argatroban. Bivalirudin (formerly Hirulog) is a synthetic peptide anticoagulant designed partly on the C-terminal sequence of hirudin, the anticoagulant of the medicinal leech (Maraganore et al., 1990); this paper studies the drug, not leech therapy.
Citation
Reference (Vancouver style)
Wieruszewski PM, Brinkman HM, Ortoleva JP, Ripoll JG, Pieterick SE, Damico KE, et al. Dosing Reliability of Direct Thrombin Inhibitors in Extracorporeal Membrane Oxygenation: A Systematic Review and Meta-Analysis. ASAIO J. 2025;71(9):691-700. doi:10.1097/MAT.0000000000002512. PMID: 40673548
Bibliographic details (authors, volume, pages, DOI) are taken from the PubMed record.
Added to ASH library: May 27, 2026 · Site last updated: November 1, 2026